{"id":56852,"date":"2026-04-28T09:14:13","date_gmt":"2026-04-28T09:14:13","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/56852\/"},"modified":"2026-04-28T09:14:13","modified_gmt":"2026-04-28T09:14:13","slug":"novartis-faces-sales-and-profit-decline-amid-entresto-generic-competition-etpharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/56852\/","title":{"rendered":"Novartis Faces Sales and Profit Decline Amid Entresto Generic Competition, ETPharma"},"content":{"rendered":"

\"\"\/London: Swiss drugmaker Novartis<\/a> reported first-quarter core operating profit<\/a> and sales below market expectations on Tuesday, as generic competition<\/a> for its top-selling heart drug Entresto<\/a> weighed on results.<\/p>\n

Shares of the drugmaker \u200cdeclined 3% \u2060in premarket \u2060trading on Tuesday.<\/p>\n

Quarterly group operating income, adjusted for special items, declined 12% to $4.9 \u200bbillion, below average analyst expectations of about $5.1 billion cited by Visible Alpha.<\/p>\n

Novartis<\/a> is \u200bnavigating its largest patent expiry in the last two decades, including for Entresto<\/a>, which made up 14% of its total net sales \u200blast year.<\/p>\n

CFO Mukul Mehta said on \u2060a call \u200cwith reporters that the results were in line \u200bwith the \u200bcompany’s internal expectations.<\/p>\n

“We do expect growth to \u2060return back to our P&L in second half of \u200bthis year,” he said.<\/p>\n

Entresto saw first-quarter sales drop \u200b42% to $1.31 billion after its U.S. patents expired and competing generics were launched. Entresto faces patent expiries in Europe starting November.<\/p>\n

Analysts were expecting sales of $1.37 billion for the first quarter ended March 31, according to data compiled by Visible Alpha.<\/p>\n

Blood disorder drug Promacta \u200cand leukemia treatment Tasigna also face competition from generics, increasing the pressure on Novartis to deliver sales growth \u200bfrom newer \u200bdrugs.<\/p>\n

Total net sales \u2060for the quarter came in at $13.11 billion, compared with analysts’ expectations of $13.40 billion.<\/p>\n

The Swiss group has said it expects its sales to \u200bdecline by $4 billion this year due to competition from generics for Entresto and the other two drugs.<\/p>\n

The Basel-based company also confirmed its full-year forecast of a low single-digit percentage core operating income drop, excluding currency swings.<\/p>\n

(Reporting by Marleen Kaesebier and Bhanvi Satija Editing by Ludwig Burger and Louise Heavens)\n <\/p>\n

Published On Apr 28, 2026 at 01:48 PM IST<\/p>\n

\n Join the community of 2M+ industry professionals.
\n Subscribe to Newsletter to get latest insights & analysis in your inbox.\n <\/p>\n

All about ETPharma industry right on your smartphone! <\/p>\n

\"\"\/ <\/p>\n","protected":false},"excerpt":{"rendered":"London: Swiss drugmaker Novartis reported first-quarter core operating profit and sales below market expectations on Tuesday, as generic…\n","protected":false},"author":2,"featured_media":56853,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[31757,3713,31755,206,31756],"class_list":{"0":"post-56852","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-core-operating-profit","9":"tag-entresto","10":"tag-generic-competition","11":"tag-novartis","12":"tag-quarterly-sales"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116481573822075973","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/56852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=56852"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/56852\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/56853"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=56852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=56852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=56852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}